Advertisement
ALNY or BIIB or IONS
Which Stock Would AI Choose? Alnylam Pharmaceuticals (ALNY) vs. Biogen (BIIB) vs. Ionis Pharmaceuticals (IONS) Stock Comparison
Key Takeaways
- ALNY leads with strong YTD gains around 20%, driven by robust TTR franchise growth including AMVUTTRA and ONPATTRO, alongside 2026 revenue guidance of $4.9-$5.3 billion.
- BIIB shows steady 1-year returns near 36%, bolstered by FDA approval for high-dose SPINRAZA and positive litifilimab data in lupus, though facing MS franchise pressures.
- IONS delivers impressive 1-year performance over 127%, fueled by Q4 revenue beats and upcoming catalysts like olezarsen PDUFA in June 2026 for severe hypertriglyceridemia (sHTG).
- All three biotech firms focus on neurology and rare diseases, with ALNY and IONS leveraging RNA interference (RNAi) platforms for superior recent momentum versus BIIB's diversified portfolio.
- Relative performance highlights ALNY's profitability shift and pipeline collaborations, while BIIB and IONS emphasize regulatory wins amid broader biotech volatility.
Introduction
This comparison examines ALNY, BIIB, and IONS, three leaders in biotechnology with overlapping exposure to neurology, rare genetic disorders, and RNA-based therapeutics. These stocks appeal to growth-oriented traders and investors tracking biotech momentum, pipeline catalysts, and relative performance in a sector sensitive to clinical data and regulatory milestones. Recent market activity underscores their contrasting trajectories: ALNY's commercial acceleration, BIIB's steady approvals, and IONS's high-upside launches. Understanding their business models, recent developments, and head-to-head metrics aids informed positioning amid evolving sentiment.
ALNY Overview and Recent Performance
Alnylam Pharmaceuticals (ALNY) pioneers RNA interference (RNAi) therapeutics, targeting genetically defined diseases with marketed products like AMVUTTRA and ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis. In recent weeks, shares have navigated volatility following Q4 2025 results, with net product revenues surging 121% year-over-year to $995 million, driven by TTR franchise expansion. Despite an initial dip on slightly missed consensus, the stock rebounded on reaffirmed 2026 guidance of $4.9-$5.3 billion in net product revenues (71% growth midpoint), highlighting AMVUTTRA's momentum in ATTR cardiomyopathy (ATTR-CM). Collaborations like the March Tenaya Therapeutics deal (up to $1.13 billion) and Viz.ai partnership for ATTR-CM care have bolstered sentiment, offsetting YTD declines from earlier peaks. Trading around $316-$317, ALNY's performance reflects optimism in RNAi leadership amid competitive TTR dynamics.
BIIB Overview and Recent Performance
Biogen (BIIB) develops therapies for neurological conditions, including multiple sclerosis (MS) franchises like TECFIDERA and SPINRAZA for spinal muscular atrophy (SMA). Recent market activity shows resilience, with shares up over 35% in the past year and YTD gains near 7%, supported by FDA approval for a high-dose SPINRAZA regimen based on the DEVOTE study. Positive Phase 2 litifilimab data in cutaneous lupus erythematosus further enhanced pipeline credibility. Q4 2025 revenues hit $2.28 billion (up slightly year-over-year), beating estimates, with growth products contributing 19% gains; however, 2026 guidance signals mid-single-digit revenue declines from MS erosion. Around $187, BIIB's sentiment balances regulatory wins against franchise maturity and competition in SMA and Alzheimer's via LEQEMBI.
IONS Overview and Recent Performance
Ionis Pharmaceuticals (IONS) specializes in antisense RNA-targeted medicines, with products like WAINUA for ATTRv-PN and TRYNGOLZA for familial chylomicronemia syndrome (FCS). Shares have delivered over 127% 1-year returns but faced YTD softness around -9%, pressured by conservative 2026 revenue guidance of $800-$825 million despite Q4 beats at $203 million. Momentum stems from FDA priority review for olezarsen in sHTG (PDUFA June 30, 2026) and zilganersen NDA acceptance for Alexander disease. TRYNGOLZA's $108 million 2025 sales underscore launch strength. Trading near $72, IONS reflects pipeline potential in larger indications, tempered by cash burn and royalty dynamics from partners like Biogen.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that trade thousands of tickers across diverse strategies, timeframes, and market conditions. These bots leverage advanced financial learning models for pattern recognition, achieving standout results like 30-day annualized returns up to 171% (e.g., TSM Trading Results at 100% win rate) and averages exceeding 127% in sectors like aerospace and tech. Selected for current relevance, they feature win rates up to 90%, low drawdowns, and styles from swing trading to high-frequency, outperforming benchmarks in volatile biotech environments. Explore these bots to align with your risk profile and enhance stock comparison insights.
Head-to-Head Comparison
ALNY, BIIB, and IONS share biotech roots in neurology and rare diseases but diverge in models: ALNY's pure RNAi focus yields highest recent growth (YTD ~20%), contrasting BIIB's diversified MS/SMA base with stable profitability yet erosion risks. IONS emphasizes antisense partnerships, offering explosive 1-year momentum (127%) but higher burn. Valuation sensitivity favors BIIB's lower P/E (~20) over ALNY's premium (134), while IONS trades on catalysts. Momentum leaders ALNY and IONS edge BIIB amid TTR/sHTG tailwinds, but BIIB's cash flow provides stability. Risks include competition in ATTR (all exposed) and regulatory hurdles; sentiment tilts to ALNY's execution versus IONS' upside trade-offs.
Tickeron AI Verdict
Tickeron’s AI currently favors ALNY based on trend consistency in TTR revenues, recent collaborations, and relative positioning versus peers. Strong Q4 beats and 2026 guidance signal sustained catalysts, with superior YTD stability over IONS' volatility and BIIB's headwinds. Probabilistic edge leans 55-60% toward ALNY outperformance in coming months, driven by observable momentum and platform validation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green whileBIIB’s FA Score has 1 green FA rating(s), and IONS’s FA Score reflects 0 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- BIIB’s FA Score: 1 green, 4 red.
- IONS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 3 TA indicator(s) are bullish while BIIB’s TA Score has 4 bullish TA indicator(s), and IONS’s TA Score reflects 4 bullish TA indicator(s).
- ALNY’s TA Score: 3 bullish, 6 bearish.
- BIIB’s TA Score: 4 bullish, 5 bearish.
- IONS’s TA Score: 4 bullish, 4 bearish.
Price Growth
ALNY (@Biotechnology) experienced а -6.62% price change this week, while BIIB (@Pharmaceuticals: Major) price change was +3.95% , and IONS (@Biotechnology) price fluctuated -0.11% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.37%. For the same industry, the average monthly price growth was +10.90%, and the average quarterly price growth was +10.70%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.08%. For the same industry, the average monthly price growth was +3.97%, and the average quarterly price growth was +7.08%.
Reported Earning Dates
ALNY is expected to report earnings on Apr 30, 2026.
BIIB is expected to report earnings on Apr 29, 2026.
IONS is expected to report earnings on Apr 29, 2026.
Industries' Descriptions
@Biotechnology (+3.37% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (+1.08% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ALNY | BIIB | IONS | |
| Capitalization | 41.5B | 26.9B | 12.4B |
| EBITDA | 631M | 2.6B | -273.12M |
| Gain YTD | -21.806 | 4.176 | -5.360 |
| P/E Ratio | 133.45 | 20.86 | N/A |
| Revenue | 3.71B | 9.89B | 944M |
| Total Cash | 2.91B | 3.82B | 2.68B |
| Total Debt | 1.28B | 6.58B | 2.07B |
ALNY | BIIB | IONS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 12 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 90 Overvalued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 52 | 100 | 45 | |
SMR RATING 1..100 | 15 | 78 | 98 | |
PRICE GROWTH RATING 1..100 | 62 | 47 | 41 | |
P/E GROWTH RATING 1..100 | 100 | 13 | 76 | |
SEASONALITY SCORE 1..100 | 50 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BIIB's Valuation (90) in the Biotechnology industry is in the same range as ALNY (94) and is in the same range as IONS (100). This means that BIIB's stock grew similarly to ALNY’s and similarly to IONS’s over the last 12 months.
IONS's Profit vs Risk Rating (45) in the Biotechnology industry is in the same range as ALNY (52) and is somewhat better than the same rating for BIIB (100). This means that IONS's stock grew similarly to ALNY’s and somewhat faster than BIIB’s over the last 12 months.
ALNY's SMR Rating (15) in the Biotechnology industry is somewhat better than the same rating for BIIB (78) and is significantly better than the same rating for IONS (98). This means that ALNY's stock grew somewhat faster than BIIB’s and significantly faster than IONS’s over the last 12 months.
IONS's Price Growth Rating (41) in the Biotechnology industry is in the same range as BIIB (47) and is in the same range as ALNY (62). This means that IONS's stock grew similarly to BIIB’s and similarly to ALNY’s over the last 12 months.
BIIB's P/E Growth Rating (13) in the Biotechnology industry is somewhat better than the same rating for IONS (76) and is significantly better than the same rating for ALNY (100). This means that BIIB's stock grew somewhat faster than IONS’s and significantly faster than ALNY’s over the last 12 months.
| ALNY | BIIB | IONS | |
|---|---|---|---|
| RSI ODDS (%) | N/A | N/A | 1 day ago 73% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 65% | 1 day ago 66% |
| Momentum ODDS (%) | 1 day ago 63% | 1 day ago 57% | 1 day ago 71% |
| MACD ODDS (%) | 1 day ago 68% | 1 day ago 55% | 1 day ago 77% |
| TrendWeek ODDS (%) | 1 day ago 65% | 1 day ago 58% | 1 day ago 66% |
| TrendMonth ODDS (%) | 1 day ago 70% | 1 day ago 58% | 1 day ago 74% |
| Advances ODDS (%) | 8 days ago 76% | 1 day ago 57% | 7 days ago 66% |
| Declines ODDS (%) | 5 days ago 66% | 12 days ago 72% | 9 days ago 65% |
| BollingerBands ODDS (%) | 1 day ago 73% | 1 day ago 48% | 1 day ago 67% |
| Aroon ODDS (%) | 1 day ago 70% | 1 day ago 64% | 1 day ago 75% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| OND | 36.56 | 2.32 | +6.78% |
| ProShares On-Demand ETF | |||
| RIET | 9.71 | 0.01 | +0.10% |
| Hoya Capital High Dividend Yield ETF | |||
| ZJUN | 27.26 | -0.01 | -0.02% |
| Innovator Equity Dfnd Prot ETF -1 YrJune | |||
| FISR | 25.86 | -0.02 | -0.10% |
| State Street® Fixed Inc Sect RotationETF | |||
| VOX | 197.50 | -1.55 | -0.78% |
| Vanguard Communication Services ETF | |||